Can Ozempic help sleep apnea? What the GLP-1 evidence shows

TL;DR

Ozempic (semaglutide) is not approved for obstructive sleep apnea and has no dedicated trial in it. Tirzepatide (Zepbound) is the GLP-1 drug the FDA approved for OSA in December 2024, after it cut breathing interruptions by 25 to 29 events an hour. No GLP-1 has been compared head-to-head with a CPAP machine.

If you searched "can Ozempic help sleep apnea," here is the honest answer: the drug you asked about is not the one with the evidence. Ozempic and Wegovy (both semaglutide) have never been tested in a dedicated sleep apnea trial. The GLP-1 medication with actual sleep apnea data, and an FDA approval, is tirzepatide, sold as Zepbound and Mounjaro.

What is obstructive sleep apnea?

Obstructive sleep apnea (OSA) is a condition where the airway repeatedly collapses during sleep, so breathing stops and restarts through the night. Doctors measure its severity with the apnea-hypopnea index (AHI): the number of times breathing pauses or turns shallow per hour. Excess weight around the neck and abdomen is one of the biggest drivers, which is why weight-loss drugs entered the conversation at all.

Which GLP-1 drug is approved for sleep apnea?

Tirzepatide, sold as Zepbound, is the only GLP-1-based medication the FDA has approved for obstructive sleep apnea. That approval landed in December 2024, based on the SURMOUNT-OSA trials. Ozempic and Wegovy are not approved for sleep apnea, and semaglutide has no dedicated OSA trial to point to.

So when people ask whether Ozempic helps sleep apnea, they are usually picturing the wrong drug. Tirzepatide acts on two gut-hormone receptors (GLP-1 and GIP); semaglutide acts on one. The head-to-head weight-loss data has generally favored tirzepatide, and you can read how the two drugs compared in SURMOUNT-5, but no one has run the sleep apnea version of that comparison.

What did the SURMOUNT-OSA trial show?

SURMOUNT-OSA was two phase 3, double-blind, randomized trials that ran for 52 weeks. One enrolled people who were not using a CPAP machine; the other enrolled people who were. In both, tirzepatide sharply lowered the apnea-hypopnea index.

Trial group	Tirzepatide	Placebo
Not using CPAP	−25.3 events/hr	−5.3 events/hr
Using CPAP	−29.3 events/hr	−5.5 events/hr

Participants also lost 17.7% to 19.6% of their body weight, versus roughly 2% on placebo. Systolic blood pressure fell by up to 9.5 mmHg, and a marker of inflammation (hsCRP) improved. For a condition long managed mainly with a machine or surgery, a medication that measurably improves it was a real change.

The same trial program also improved how rested people felt during the day. We covered those patient-reported sleep quality and fatigue results separately, because feeling less tired and lowering the AHI are two different measures.

Does the benefit come only from weight loss?

This is where the science gets less settled. Most of the benefit almost certainly comes from losing weight, which reduces the fat and tissue crowding the airway. But the review authors argue GLP-1 drugs may act on sleep apnea through other routes as well.

Early findings point to three: lower inflammation independent of weight, direct effects at the carotid body (a small organ that helps regulate breathing and the nervous system), and central brain effects on sleep and wakefulness. Researchers are still investigating whether any of these matter in practice. As the authors put it plainly, it is unresolved whether the OSA improvement is mainly weight loss or a direct effect on the disease itself.

Can a GLP-1 drug replace your CPAP machine?

Not on the current evidence, and this part matters most. SURMOUNT-OSA never compared tirzepatide directly against a CPAP machine, so no one can claim the drug works as well as CPAP. The authors are explicit that no such conclusion can be drawn from how the study was designed.

There is also a signal that the two do different jobs. In research on liraglutide, an older GLP-1, only CPAP and not the drug alone improved vascular inflammation and unstable artery plaque. And when a GLP-1 was added on top of CPAP, people did better than with CPAP alone. That points toward combining the treatments, not swapping one for the other.

Liraglutide's own trial, SCALE Sleep Apnea, is a useful reality check on the older drugs: it lowered the AHI by 12.2 events an hour versus 6.1 on placebo over 32 weeks, with about 5.7% weight loss. Helpful, but a long way from tirzepatide's numbers, and still not a CPAP replacement.

The practical point: do not stop using a CPAP machine because you started a GLP-1. Talk to the doctor who manages your sleep apnea before changing anything, and keep in mind that stopping tirzepatide tends to bring the weight, and the apnea, back.

Who were these results actually for?

The SURMOUNT-OSA participants were adults with obesity and moderate-to-severe sleep apnea. That scope matters, because the approval and the numbers apply to that group, not to everyone who snores or feels tired. If your sleep apnea is mild, or if it is not driven by excess weight, the trial does not tell you what to expect.

The drug is also not side-effect free. GLP-1 medications commonly cause nausea, vomiting, diarrhea and constipation, especially in the first weeks and during dose increases. Those GLP-1 side effects are the trade-off against the benefit, and they are worth weighing with a clinician rather than reading the AHI numbers on their own. Anyone with sleep apnea should still be diagnosed and monitored by a sleep specialist, drug or no drug.

What this means if you have sleep apnea

• Ozempic and Wegovy (semaglutide) are not approved for sleep apnea and have no dedicated trial in it.
• Tirzepatide (Zepbound) is the one GLP-1 drug FDA-approved for OSA, since December 2024.
• In SURMOUNT-OSA, tirzepatide cut breathing interruptions by 25 to 29 events an hour over 52 weeks.
• No GLP-1 has been tested head-to-head against CPAP, so a drug is not a proven CPAP replacement.
• Rapid weight loss on any GLP-1 thins out your diet, so protein and vitamins while on GLP-1 still matter.

Where nutrition fits in

Whichever GLP-1 you take, the weight loss comes from eating far less, and that is where the diet gets thin. Daytime tiredness is easy to pin on poor sleep alone, but low iron, low vitamin B12 and low vitamin D cause the same drag, and all three slip more easily when you eat less. Treating sleep apnea and covering nutrient gaps are two separate jobs.

GLP-1 supplements can help close the nutrient gap that comes from eating less. They do not treat sleep apnea, and no supplement should be sold as if it does. If you want a simple framework, our supplement protocol and monitoring guide lay out what to take and what to test. GLP-1 Shield is built around that gap, not around replacing anything your doctor prescribes.

Frequently asked questions

Can Ozempic (semaglutide) treat sleep apnea?

Ozempic and Wegovy, both semaglutide, are not approved for sleep apnea, and semaglutide has not been tested in a dedicated sleep apnea trial. Any benefit would most likely come from weight loss rather than a proven effect on the condition. The GLP-1 drug with actual OSA data is tirzepatide.

Which GLP-1 medication is FDA-approved for sleep apnea?

Tirzepatide, sold as Zepbound, is the only GLP-1-based medication the FDA has approved for obstructive sleep apnea. The approval came in December 2024, based on the SURMOUNT-OSA trials in adults with obesity and moderate-to-severe OSA.

Can a GLP-1 drug replace my CPAP machine?

No study has compared a GLP-1 drug head-to-head against CPAP, so a GLP-1 is not a proven CPAP replacement. Early research suggests combining CPAP with a GLP-1 works better than CPAP alone. Do not stop using CPAP without talking to the doctor who manages your sleep apnea.

How much does tirzepatide lower the apnea-hypopnea index?

In the SURMOUNT-OSA trials, tirzepatide lowered the apnea-hypopnea index by 25.3 events an hour in people not using CPAP and 29.3 events an hour in people using it, over 52 weeks. Placebo lowered it by about 5 events an hour. Individual results vary.